GANX - NASDAQ

Gain Therapeutics, Inc.

GANX·NASDAQ

$1.88

+4.7%

HealthcareBiotechnology

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$79.98M

EPS-0.6100

P/E Ratio-3.07

Earnings Date08/06/2026

ganx

Short Term Debt

Last Annual Value

220.75K

3-Year CAGR

27%

5-Year CAGR

58%

10-Year CAGR

Adjust for Inflation

Gain Therapeutics, Inc. Competitors Analysis of Short Term Debt

GANX · NASDAQ

Company	Short Term Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
Gain Therapeutics, Inc. NASDAQ:GANX	220.75K	22.9%	16.3%	N/A
Fortress Biotech, Inc. NASDAQ:FBIO	0.00	N/A	N/A	N/A
CervoMed Inc. NASDAQ:CRVO	0.00	N/A	N/A	N/A
Lite Strategy, Inc. NASDAQ:LITS	0.00	N/A	N/A	N/A
Clene Inc. NASDAQ:CLNN	4.88M	-37.0%	N/A	N/A
Werewolf Therapeutics, Inc. NASDAQ:HOWL	1.75M	-36.0%	N/A	N/A
Immix Biopharma, Inc. NASDAQ:IMMX	139.34K	N/A	22.7%	N/A
PMV Pharmaceuticals, Inc. NASDAQ:PMVP	403.00K	N/A	N/A	N/A
Prelude Therapeutics Incorporated NASDAQ:PRLD	2.74M	N/A	N/A	N/A
Vaxart, Inc. NASDAQ:VXRT	2.98M	-7.8%	28.9%	31.0%
NRx Pharmaceuticals, Inc. NASDAQ:NRXP	316.00K	-67.4%	-9.4%	N/A

Gain Therapeutics, Inc. Fair Value Envelope

GANX · NASDAQ

Our analysis suggests that GANX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.875, this represents a potential HIDDEN relative to our calculated worth for Gain Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $1.875

Related Guides

Blog Categories

Continue your GANX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.